PUBLIC COMPANY
save$GILDGILEAD SCIENCES, INC.
$GILD138.36+0.16%Foster City, CA, USupdated 1d ago
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
community read0 votes
🐶 often sniffed alongside
top 3pipeline
33
marketed
15
phase 3
3
catalysts ytd
10
approvals ytd
5
recalls ytd
0
Pipeline(33)
view full pipeline →pipeline depth33 products
4Phase 15Phase 23Phase 315Marketed4Unknown2pre_registration
Marketed
(bictegravir sodium + emtricitabine + tenofovir alafenamide)
Human Immunodeficiency Virus (HIV) Infections (AIDS)
Marketed(cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate)
Human Immunodeficiency Virus (HIV) Infections (AIDS)
Marketed(cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate)
Human Immunodeficiency Virus (HIV) Infections (AIDS)
Marketed(emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide)
Human Immunodeficiency Virus (HIV) Infections (AIDS)
Marketed(emtricitabine + rilpivirine hydrochloride + tenofovir disoproxil fumarate)
Human Immunodeficiency Virus (HIV) Infections (AIDS)
Marketed(emtricitabine + tenofovir alafenamide)
Human Immunodeficiency Virus (HIV) Infections (AIDS)
Marketed(ledipasvir + sofosbuvir)
Hepatitis C
Marketed(sofosbuvir + velpatasvir + voxilaprevir)
Hepatitis C
MarketedIDELALISIB
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Marketedaztreonam lysine
Cystic Fibrosis
Marketedcobicistat
Human Immunodeficiency Virus (HIV) Infections (AIDS)
Marketedemtricitabine
Human Immunodeficiency Virus (HIV) Infections (AIDS)
Upcoming
Recent(90d)
earnings (2)
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 15, 26SELLDickinson Andrew D· Chief Financial Officer−$423K↗
- Apr 15, 26SELLMercier Johanna· Chief Comm & Corp Aff Officer−$423K↗
- Mar 27, 26SELLO'Day Daniel Patrick· Chairman & CEO−$1.37M↗
- Mar 16, 26SELLMercier Johanna· Chief Comm & Corp Aff Officer−$433K↗
- Mar 16, 26SELLDickinson Andrew D· Chief Financial Officer−$433K↗
- Feb 27, 26SELLO'Day Daniel Patrick· Chairman & CEO−$932K↗
- Feb 27, 26SELLO'Day Daniel Patrick· Chairman & CEO−$501K↗
- Feb 27, 26SELLO'Day Daniel Patrick· Chairman & CEO−$15K↗
routine RSU / option mechanics (6)
- Mar 10, 26tax coverO'Day Daniel Patrick · Chairman & CEO9,767 sh
- Mar 10, 26tax coverMercier Johanna · Chief Comm & Corp Aff Officer3,216 sh
- Mar 10, 26tax coverDickinson Andrew D · Chief Financial Officer3,147 sh
- Mar 10, 26tax coverBerger Dietmar · Chief Medical Officer1,063 sh
- Mar 10, 26tax coverCain Wettan Keeley M · EVP Gen Counsel, Legal & Comp606 sh
- Mar 10, 26grantMercier Johanna · Chief Comm & Corp Aff Officer35,880 sh
🐶 Hiring Signal
next earnings Oct 29, 2026
Where GILEAD SCIENCES, INC. is staffing up — a leading indicator of pipeline and commercial priorities.
News
- Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mountsHIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.biospace · 10d ago
- STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate caseThe California Supreme Court sided with Gilead Sciences in a closely watched case over whether the company had a "duty" to innovate.stat · 12d ago
- Merck stages expanded access to monthly HIV PrEP pill ahead of approvalFollowing in the footsteps of Gilead, Merck has signed voluntary licensing agreements to enable access to its investigational HIV PrEP pill alimatravir ahead of any regulatory submissions.fiercebiotech · 22d ago
- Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onRoche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…biospace · 23d ago
- Biopharma layoffs must double in H2 for 2026 to match 2025 cutsWith fewer biopharmas making or planning workforce reductions so far year over year, layoff round size and M&A impact on headcounts will likely shape the number of employees who are ultimately on t…biospace · 23d ago
- Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease studyA new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competi…biopharma_dive · 24d ago
- Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharmaTakeda’s cuts will go the deepest, affecting over 4,700 employees. Layoffs tied to M&A activity include BioNTech letting go of around 800 people at CureVac.biospace · 1mo ago
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) InfectionToday, the U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarr…fda_press · 2mo ago
- Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast CancerCapivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.onclive · 3mo ago
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that